High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus
- 18 September 2015
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 34 (12) , 2071-2077
Abstract
The purpose of this study was to clarify the factors related to silent osteonecrosis of the femoral head (ONFH) in patients with systemic lupus erythematosus (SLE). Seventy-eight patients with SLE were selected on the basis of having been newly diagnosed and requiring high-dose prednisolone, including pulse therapy with methylprednisolone, as the initial treatment. All the patients initially underwent MRI at 3 months after the start of corticosteroid treatment to detect any early changes in the femoral head. These examinations were then performed again 3 months later. Laboratory parameters were evaluated at the start of steroid treatment and at 1 month thereafter. By 3 months after the start of corticosteroid treatment, silent ONFH was diagnosed by MRI in 21 patients (26.9 %), being bilateral in 11 patients and unilateral in 10. The occurrence of silent ONFH was not related to SLE disease activity index, serological activity, or renal function; it was also unrelated to body mass index (BMI), body surface area (BSA), and the initial dose of prednisolone per unit body weight. However, the total cholesterol level at 4 weeks after the start of steroid treatment tended to be higher in patients with silent ONFH. Patients with a higher triglyceride level showed a significantly higher frequency of silent ONFH both before (p = 0.002) and 4 weeks after (p = 0.036) steroid initiation. A high triglyceride level is an important risk factor for silent ONFH in patients with SLE, and large-scale epidemiologic surveys of such early events are needed in this patient population.Keywords
This publication has 26 references indexed in Scilit:
- Pronounced risk of nontraumatic osteonecrosis of the femoral head among cigarette smokers who have never used oral corticosteroids: a multicenter case–control study in JapanJournal of Orthopaedic Science, 2012
- The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based studyHypertension Research, 2009
- Pitavastatin may Reduce Risk of Steroid-induced Osteonecrosis in Rabbits: A Preliminary Histological StudyClinical Orthopaedics and Related Research, 2008
- Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control studyAnnals of the Rheumatic Diseases, 2006
- Right Bundle-Branch Block Ventricular TachycardiasCirculation, 2004
- Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific RegionCirculation, 2004
- Oxidative stress and vascular permeability in steroid-induced osteonecrosis modelJournal of Orthopaedic Science, 2004
- Sustained hemostatic abnormality in patients with steroid-induced osteonecrosis in the early period after high-dose corticosteroid therapyJournal of Orthopaedic Science, 2000
- The Pathogenesis and Prevention of Steroid Induced OsteonecrosisClinical Orthopaedics and Related Research, 2000
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992